{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=17",
    "query": {
      "condition": "B-cell Non-Hodgkin Lymphoma (B-NHL)",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1092,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma+%28B-NHL%29&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T08:53:10.767Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05685173",
      "title": "A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Non-Hodgkins Lymphoma (B-NHL)"
      ],
      "interventions": [
        {
          "name": "Odronextamab",
          "type": "DRUG"
        },
        {
          "name": "REGN5837",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2023-04-20",
      "completion_date": "2030-01-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Santa Monica, California • Louisville, Kentucky + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05685173"
    },
    {
      "nct_id": "NCT00002673",
      "title": "Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "infection prophylaxis and management",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "12 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "1995-06",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2010-06-17",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002673"
    },
    {
      "nct_id": "NCT06091254",
      "title": "A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Follicular Lymphoma (FL)"
      ],
      "interventions": [
        {
          "name": "Odronextamab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone/prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 822,
      "start_date": "2023-12-12",
      "completion_date": "2029-11-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Noblesville",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06091254"
    },
    {
      "nct_id": "NCT02061761",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "BMS-986016",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BMS-936558",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2014-03-13",
      "completion_date": "2022-02-16",
      "has_results": true,
      "last_update_posted_date": "2023-03-24",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 8,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061761"
    },
    {
      "nct_id": "NCT00003397",
      "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 25,
      "start_date": "1998-09",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-04",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003397"
    },
    {
      "nct_id": "NCT01429025",
      "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory/Relapsed Indolent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bendamustine",
          "type": "DRUG"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2012-05",
      "completion_date": "2019-07-01",
      "has_results": false,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 17,
      "location_summary": "Clive, Iowa • Des Moines, Iowa • Sioux City, Iowa + 3 more",
      "locations": [
        {
          "city": "Clive",
          "state": "Iowa"
        },
        {
          "city": "Clive",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01429025"
    },
    {
      "nct_id": "NCT05098613",
      "title": "Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "B-cell Non-Hodgkin Lymphoma (B-NHL)",
        "Mantle Cell Lymphoma (MCL)",
        "CNS Lymphoma"
      ],
      "interventions": [
        {
          "name": "CD19x22 CAR T Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2021-12-21",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05098613"
    },
    {
      "nct_id": "NCT02362997",
      "title": "Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Peripheral T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2015-04",
      "completion_date": "2023-06",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02362997"
    },
    {
      "nct_id": "NCT00897923",
      "title": "Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "radionuclide imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "indium In 111-labeled autologous peripheral blood mononuclear cells",
          "type": "RADIATION"
        },
        {
          "name": "indium In 111-labeled autologous polymorphonuclear leukocytes",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 17,
      "start_date": "2003-09",
      "completion_date": "2012-02-10",
      "has_results": false,
      "last_update_posted_date": "2017-03-22",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Rochester, Minnesota",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897923"
    },
    {
      "nct_id": "NCT00068315",
      "title": "Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hematopoietic/Lymphoid Cancer",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Splenic Marginal Zone Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2003-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-10-14T08:53:10.767Z",
      "location_count": 7,
      "location_summary": "Canton, Ohio • Cleveland, Ohio • Middleburg Heights, Ohio + 3 more",
      "locations": [
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Middleburg Heights",
          "state": "Ohio"
        },
        {
          "city": "Orange",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068315"
    }
  ]
}